ERBB2 and breast carcinoma: We observed that high level of β2-AR was closely associated with LNM and poor DFS in Her2-positive breast cancer patients, indicating that β2-AR is a potential prognostic biomarker for survival and tumor recurrence in Her2-overexpressing breast cancers.